Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Kolbaba

Internal Medicine Wheaton, IL Medical Doctor

NPI 1396776613 CMS profile 290218

7 Blanchard Cir, Suite 106, Wheaton, IL 60187

Open in the dashboard

General payments

$10,611

636 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Kolbaba of Wheaton, IL is reported in the CMS Open Payments database as having received $10,611 across 636 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,311 67
2024 General $1,529 81
2023 General $1,536 83
2022 General $1,543 90
2021 General $1,559 100
2020 General $1,539 94
2019 General $1,594 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Kolbaba
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Kolbaba were reported at $1,311. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Kolbaba Internal Medicine median Middle half National median
2019 $1,594 $159 $48–$570 $163
2020 $1,539 $119 $33–$402 $114
2021 $1,559 $135 $37–$521 $132
2022 $1,543 $141 $42–$496 $149
2023 $1,536 $149 $45–$519 $160
2024 $1,529 $154 $47–$537 $164
2025 $1,311 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,070 66 payments
  2. Novo Nordisk Inc $1,035 56 payments
  3. Kowa Pharmaceuticals America, Inc. $963 109 payments
  4. AstraZeneca Pharmaceuticals LP $791 44 payments
  5. Amgen Inc. $783 51 payments
  6. Lilly USA, LLC $672 35 payments
  7. Janssen Pharmaceuticals, Inc $658 42 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $650 30 payments
  9. GlaxoSmithKline, LLC. $475 19 payments
  10. Pfizer Inc. $450 21 payments
  11. Other $3,064 163 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,481 632 payments
  2. Education $115 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15 1 payment
Products named General payments · program years 2019–2025
  1. Livalo $954 108 payments
  2. RYBELSUS $646 34 payments
  3. Ozempic $646 35 payments
  4. UBRELVY $612 36 payments
  5. Bystolic $525 65 payments
  6. FARXIGA $473 26 payments
  7. TRELEGY ELLIPTA $461 18 payments
  8. Otezla $441 32 payments
  9. XARELTO $431 31 payments
  10. Repatha $411 26 payments
  11. Other $9,578 514 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,265

Median for Internal Medicine: 777

Drug cost

$395,058

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 84 $80,866
Ozempic Semaglutide Brand 43 $41,670
Mounjaro Tirzepatide Brand 30 $34,772
Xarelto Rivaroxaban Brand 42 $34,560
Myrbetriq Mirabegron Brand 55 $26,545
Rybelsus Semaglutide Brand 15 $22,689
Jardiance Empagliflozin Brand 21 $20,919
Repatha Sureclick Evolocumab Brand 16 $14,306
Januvia Sitagliptin Phosphate Brand 12 $13,318
Repatha Syringe Evolocumab Brand 12 $10,804

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$238,530

Of which drugs: $33,763

Medicare patients

334

Average age 77

Services billed

4,584

182 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 26%
Diabetes 25%
Osteoporosis 25%
Depression 20%
Cancer 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 86 86 $25,091
Vaccine for influenza for injection into muscle 90662 Office 101 103 $8,358
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 522 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $99
$99 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $73
$73 — —
Otezla
  • Amgen Inc. $72
$72 — —
Repatha
  • Amgen Inc. $72
$72 28 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

636 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record